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Abstract
Motivation: Correct and rapid determination of Mycobacterium tuberculosis (MTB) resistance against
available tuberculosis (TB) drugs is essential for the control and management of TB. Conventional
molecular diagnostic test assumes that the presence of any well-studied single nucleotide polymor-
phisms is sufficient to cause resistance, which yields low sensitivity for resistance classification.
Summary: Given the availability of DNA sequencing data from MTB, we developed machine learn-
ing models for a cohort of 1839 UK bacterial isolates to classify MTB resistance against eight anti-
TB drugs (isoniazid, rifampicin, ethambutol, pyrazinamide, ciprofloxacin, moxifloxacin, ofloxacin,
streptomycin) and to classify multi-drug resistance.
Results: Compared to previous rules-based approach, the sensitivities from the best-performing
models increased by 2-4% for isoniazid, rifampicin and ethambutol to 97% (P < 0.01), respectively;
for ciprofloxacin and multi-drug resistant TB, they increased to 96%. For moxifloxacin and ofloxacin,
sensitivities increased by 12 and 15% from 83 and 81% based on existing known resistance alleles to
95% and 96% (P < 0.01), respectively. Particularly, our models improved sensitivities compared to
the previous rules-based approach by 15 and 24% to 84 and 87% for pyrazinamide and streptomycin
(P < 0.01), respectively. The best-performing models increase the area-under-the-ROC curve by 10%
for pyrazinamide and streptomycin (P < 0.01), and 4–8% for other drugs (P < 0.01).
Availability and implementation: The details of source code are provided at http://www.robots.ox.
ac.uk/~davidc/code.php.
Contact: david.clifton@eng.ox.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Tuberculosis (TB) was one of the leading 10 causes of death world-
wide, ranking above HIV/AIDS as the prominent cause of death
from infectious disease. Drug-resistant TB has emerged as a substan-
tial concern for public health and threatens global TB control.
The World Health Organisation (WHO) reported in 2017 (WHO,
2017) that an estimated 4.1% (95% confidence interval [CI]: 2.8–
5.3%) of new cases and 19% (95% CI: 9.8–27%) of previously
treated cases had multi-drug resistant TB (MDR-TB), defined as
being resistant to isoniazid INH and rifampicin RIF) or rifampicin-
resistant TB (RR-TB). WHO now recommends that all RR-TB cases
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be treated with an MDR-TB treatment regime (WHO, 2016). The
emergence and spread of drug-resistant TB have been reported to be
related to vulnerabilities of current TB-control efforts (Cohen et al.,
2015), biological factors (Casali et al., 2014), treatment-related risk
factors (Ford et al., 2013), compensatory evolution of bacteria
(Comas et al., 2011), population displacement and political instabil-
ity (Eldholm et al., 2016).
One critical challenge in tackling the global TB epidemic is
timely diagnosis and correct treatment. Rapid molecular diagnostic
tests help to ensure early detection and prompt treatment; these tests
assume the presence of a single nucleotide polymorphism (SNP),
which is one of the previously identified SNPs, is sufficient to cause
resistance. Such tests are effective with the most common mutations
causing resistance to drugs, but their underpinning technology
restricts them to a relatively small number of targets per drug.
Research to date has focused on the identification of the described
multivariate associations (Coll et al., 2015; Farhat et al., 2013;
Georghiou et al., 2012; Walker et al., 2015; Zhang et al., 2013).
However, methods for identifying such multivariate association can
be of limited utility in light of the fact that association is still poorly
understood for some anti-TB drugs. Compounding this effect, the
genetic basis of drug resistance is more complex than anticipated:
resistance-related genes are likely to contain nonsynonymous SNPs
associated with drug resistance as a result of drug pressure (Zhang
et al., 2013); and mutations that interact in a complex manner could
produce high-level resistance to a specific drug (Safi et al., 2013).
In countries with the highest incidence of MDR-TB, it was found
that more than 30% of MDR clinical isolates had compensatory
mutations (Comas et al., 2011).
Multivariate association between genetic variants can be
explored with predictive models based on machine learning.
Previous studies have adopted a number of such algorithms to pre-
dict Mycobacterium tuberculosis (MTB) resistance; e.g. logistic
regression (Zhang et al., 2013) and random forests (?). However,
a thorough evaluation of potentially applicable methods for the
classification of MTB drug-resistance has not been reported.
In this paper, using a large collection of MTB isolates, we eval-
uated the ability of different models to classify drug resistance for
the four first-line drugs, several second-line drugs and MDR-TB.
Our models achieved comparable or better classification of
drug resistance in comparison to the direct association that
depends solely on any resistance-determinants previously identi-
fied in the literature. Our results validate the use of machine
learning algorithms for the identification of MTB resistance, and
support the hypothesis that previously unknown multivariate
associations and interactions contribute to resistance to several
anti-TB drugs.
2 Materials and methods
2.1 Specimen and laboratory phenotyping
We included 1839 samples from Walker et al. (2015). On all study
isolates, DST was performed for each drug through an initial screen
for resistance in liquid culture, which was then confirmed using
Lowenstein Jensen methods. Up to 11 drugs were assayed, including
isoniazid (INH), rifampicin (RIF), ethambutol (EMB), pyrazinamide
(PZA), amikacin (AK), capreomycin, (CAP), ciprofloxacin (CIP),
kanamycin (KAN), moxifloxacin (MOX), ofloxacin (OFX) and
streptomycin (SM).
2.2 DNA sequencing
The details of DNA sequencing refer to Walker et al. (2015).
Nucleotide bases were called using standard filters on sequencing
and alignment quality, as well as the number of reads for each base.
After filtering, the nucleotide bases at certain positions that could
not be called with confidence were denoted as null calls and not
used in our analysis.
2.3 Genomic data pre-processing
23 candidate genes and their 100 base-pair upstream regions were
targeted in this study (As described in Supplementary Material A).
We limited our investigation to these genes because each has at least
one previously described drug-resistance mutation [the source
papers related to these genes were summarized in Walker et al.
(2015)], allowing us to focus our investigation upon those areas of
the genome in which we have a high prior belief of involvement.
M.tuberculosis lineage was assigned based on polymorphisms
described in the literature (Feuerriegel et al., 2014; Stucki et al.,
2012) and corroborated by a previously published phylogeny
(Walker et al., 2015). We reported every nucleotide site that differed
from the reference genome, identified the corresponding amino acid
substitution where there was one, and differentiated between differ-
ent amino acids at those variant sites. We therefore considered the
variant sites with amino acid substitution as SNP. The presence of a
SNP in the isolate was represented by a binary variable, with 1 indi-
cating the presence of the SNP and 0 indicating absence. The aver-
age number of SNPs per isolate was 6, ranging between 1 and 47.
Null calls were considered to be SNPs if the base with the highest
percentage of reads did not agree with the reference. In total across
the 1839 isolates, 2629 SNPs were found in the 23 candidate genes.
3 Results
3.1 Phenotype
Our study included 1839M.tuberculosis isolates, representing all
the major TB clades [the phylogenetic tree is given in Supplementary
Fig. S1 by Walker et al. (2015)]. Each isolate underwent culture-
based drug-susceptibility testing to a maximum of 11 anti-TB drugs.
Not every isolate was tested against all drugs. The four first-line
anti-TB drugs were tested on the majority of isolates (Fig. 1, left
panel). Of the 1811 isolates that were tested against INH, 266
(15%) were resistant and 1545 (85%) were susceptible; the ratio of
the number of the resistant and susceptible isolates was approxi-
mately 1:5.7 for INH. In the case of EMB, RIF and PZA, the num-
bers of resistant isolates were only 47, 97 and 59, representing 3%,
6% and 3% of the total number, respectively. Correspondingly, the
ratio of the two classes declined to 1:36, 1:16.8 and 1:28.2, respec-
tively. Regarding the second-line drugs, no more than 400 isolates
were tested against individual drugs, meanwhile the number of the
resistant versus susceptible isolates was approximately 1:10. Since
there were few AK, KAN and CAP-resistant isolates, these three
drugs were not be investigated in the following analysis.
Co-occurrence of resistance was frequently observed for the tested
drugs in our cohort (Fig. 1, rightmost). Within the 11 drugs, single-
drug-resistant isolates only existed for INH, RIF, PZA and streptomy-
cin (SM) (only cells that correspond to INH, RIF, PZA and SM on the
diagonal are non-zero entries). Of 320 isolates that were resistant to
at least one of the eleven drugs, 65% was mono-resistant to single
drug, where 170 (53%), 8 (2.5%), 20 (6%) and 2 (0.6%) were mono-
resistant to INH, RIF, EMB and PZA, respectively. Of these 320 iso-
lates, 81 (25%) was resistant to both NIH and RIF, 19 (6%) was both
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EMB and PZA resistance. In other cases of resistance to any two first-
line drugs, the number of the isolates was similar (10–12% of the 320
isolates); they were the same for the resistance to both SM and any
first-line drug. For all other two-drug resistance co-occurrence, the
number of the isolates was no more than 16 (5%).
3.2 Clustering
We performed both principal component analysis (PCA) and a
sparse logistic version (SL-PCA) to explore the underlying structure
of genetic variation within our cohort of bacterial isolates. For these
1839 isolates, 2629 SNPs were found in 23 genes in which previous
studies had identified one or more known resistance-conferring
mutation. Both the PCA and SL-PCA reduced the dimensionality of
2629 to 2. Figure 2 shows the resulting structure, with resistance
shown in terms of INH-resistance and sub-lineage, a separate anno-
tation obtained by phylogeny analysis introduced in Section 3.3,
independent of phenotype. The use of conventional PCA results in
compact structure, with little variation for each cluster and a ‘Y’
shape in the subspace spanned by the first two principal components
(PCs), which separates the various cluster. Comparatively, SL-PCA
produces structure that reveals variation for all clusters and
the resistant/susceptible phenotype. Using the first two logistic
PCs, four clusters (EAI, Haarlem_Ghana_X, Delhi_CAS and
Bovis_Africanum) were well-separated and positioned around a cen-
tral cluster. We term this cluster C1, which is composed of isolates
from the Beijing, EuroAmer, LAM, Tur and Uganda clades. Within
this C1 cluster, conventional PCA shows poor separability between
INH-resistant and susceptible classes. Overall, SL-PCA is more
informative than PCA: SL-PCA can be used to identify clusters and
provide better separation for resistant and susceptible classes within
the cluster C1. We performed classification analysis both on entire
dataset and on several selected clusters; the latter is provided in
Supplementary Material I.
3.3 Direct association
Existing methods classify drug resistance based on the presence of
any determinant from a library of such determinants that has been
assembled from the literature; we term this method ‘direct
Fig. 1. Phenotype of 1839 isolates. left: bar plot of phenotype availability for the different drugs. right: heatmap quantifying the number of instances of co-occur-
rence of resistance between drugs normalized by total number of isolates resistant to at least one drug. Off-diagonal elements show co-occurrence of resistance
between different drugs; on-diagonal elements show cases which are resistant to a single drug
Fig. 2. PCA (upper row) and SL-PCA (lower row) for all clades [Clades are defined based on the whole genome sequences (not just resistance genes). Interested
readers are referred to Benavente et al. (2015).] (left plots) and cluster C1 (right plots) in terms of INH resistance (C1: Beijing, Euro, LAM, Tur and Uganda) (Color
version of this figure is available at Bioinformatics online.)
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association’ (DA). We examined the use of two such libraries: (i) the
‘Dream TB’ database and (ii) those described in an existing study
(Walker et al., 2015). We term the methods using these two libraries
DA-D and DA-L, respectively (as listed in Supplementary Material B
and C, respectively). To classify resistance against a given drug, we
applied an ‘OR’ rule: if any of the mutations associated with a given
drug in the library were present for a given isolate, the isolate was
labelled as being resistant to that drug. Full results for resistance
classification by the DA methods are provided in Supplementary
Material F.
3.4 Classification using machine learning methods
We investigated seven machine learning classifiers, including include
logistic regression with L1 and L2 regularisation (LR-L1 and LR-
L2), support vector machine with L2 regularisation and a radial
basis function kernel (SVM-L2 and SVM-RBF), random forest
(RF), a product-of-marginals model (PM) and a class-conditional
Bernoulli mixture model (CBMM) (the methodology details and
learning scheme are provided in Supplementary Material E and D,
respectively). While evaluating all methods, we repeatedly and ran-
domly selected the susceptible isolates from susceptible class in each
experiment, to give the same number as in the resistant class in terms
of individual drugs. The detail regarding dataset generation is illus-
trated in Supplementary Material D.
Three sets of features, F1–F3, were considered, to evaluate their
performances. Feature set F1 is the baseline feature set (all SNPs
found within 23 candidate genes, Supplementary Material A).
Feature set F2 contains only those SNPs that were previously sus-
pected of being resistance-determinants [108 SNPs reported in
(Walker et al., 2015)]. Feature set F3 is a subset of F1 given a partic-
ular drug (where genes with only resistance-determinants to that
drug are included). F3 therefore reflects what could be considered as
direct determinants, whereas F2 incorporates the possibility of using
resistance co-occurrence (Fig. 1) within all direct determinants
for 11 drugs to inform prediction, and F1 interprets resistance
co-occurrence on a larger scale.
Figure 3 shows comparisons in AUC performance for the seven
machine learning classifiers, for the three feature sets, using eight
drugs [amikacin (AK), clarithromycin (CAP) and Kanamycin (KAN)
were excluded due to under 10 resistant isolates]. The drugs can be
classified into three groups: i) the drugs where almost all classifiers
were robust on the three feature sets (INH, RIF, EMB and MDR); ii)
the drugs where the classifiers were better with feature sets F1 and
F2 (PZA and SM); iii) the drugs where the classifiers were better
with feature set F3 (MOX and OFX). Detection of resistance to
INH, RIF, EMB and MDR may be seen to be robust to the choice of
classifier, with all classifiers achieving at least 93% AUC for all fea-
ture sets (except for the RF with F1 and F3 in the case of CIP). The
AUC performances of all classifiers for PZA and SM were improved
at least 10% with F1 and F2 compared with F3, respectively (the
SNPs that were statistically important for predicting PZA and SM
resistance based on PM model, which outputs probability for
presence or absence of a SNP given a Beta prior, are listed in
Supplementary Material J). MOX and OFX resistance identification
was most challenging, with all classifiers achieving AUC values
below 90% for feature sets F1 and F2. In particular, the average per-
formance with F3 was noticeably better than those with either F1 or
F2 with at least 85% mean AUC. Based on variable importance
measures in RF, the SNPs within the suspect genes given the investi-
gated drugs are listed in Supplementary Material K.
3.5 Comparing existing methods with machine-learning
methods
We compared DA resistance classification with the seven machine
learning classifiers. We additionally performed an experiment in
which we removed a set of four commonly occurring SNPs
(gyrA_E21, gyrA_S95, gyrA_G668, katG_R463) that are known
not to be causally involved with resistance from feature set F1. As
shown in Table 1, the best-performing machine learning classifier
yielded higher AUC values in comparison to the baseline DA method
for all examined drugs (P < 0.01). Our models yielded results with
improved mean sensitivity in resistance classification for all drugs in
Fig. 3. Classification performance in AUC for seven classifiers across eight anti-TB drugs and MDR-TB with the F1, F2 and F3 feature sets. While the horizontal
axis is discrete, dashed lines are shown between data for ease of viewing (Color version of this figure is available at Bioinformatics online.)
Classifying resistance of TB using machine learning methods 1669
Downloaded from https://academic.oup.com/bioinformatics/article-abstract/34/10/1666/4731737
by Institute of Child Health/University College London user
on 21 May 2018
comparison to DA-L (P < 0.01), while maintaining mean specificity
above 90%.
Compared to DA-L method, the sensitivities from the best-
performing models increased by 2–4% for isoniazid, rifampicin and
ethambutol to 97% (P < 0.01), respectively; for ciprofloxacin and
multi-drug resistant TB, they increased to 96%. For moxifloxacin
and ofloxacin, sensitivities increased by 12 and 15% from 83 and
81% based on existing known resistance alleles to 95% and 96%
(P < 0.01), respectively. Particularly, our models improved sensitiv-
ities compared to the previous rules-based approach by 15 and 24%
to 84 and 87% for pyrazinamide and streptomycin (P < 0.01),
respectively. The best-performing models increase the area-under-
the-ROC curve by 10% for pyrazinamide and streptomycin
(P < 0.01), and 4–8% for other drugs (P < 0.01). Meanwhile, the
specificities for all drugs dropped by 4–10%. Removing the known
disassociated mutations (D.SNPs) altered the mean AUC by no more
than 0.8% for all drugs. In addition, for several interesting subclades
(e.g. EAI, CAS, Beijing and C1), the best classifiers also improved
the mean sensitivity and AUC for INh, EMB, RIF, PZA and MDR
(Supplementary Material I).
4 Discussion
A machine learning approach towards MTB resistance classification
is both viable and, particularly when the underlying biologic mecha-
nisms are less well-studied, offers improvement upon the current
clinical state-of-the-art. It is typically thought that sensitivity is most
important in our application, because failure to identify resistance
can harm patients: in such cases, treatment would proceed using
drugs that do not affect the (resistant) bacteria. Comparatively, the
DA methods are generally very specific, but not as sensitive as
machine learning methods. In our study, specificity often decreased
with the machine learning methods, which could be due to some sus-
ceptible isolates containing determinants classified as causing resist-
ance, but were labeled as drug susceptible due to limitations in the
phenotypic methods used to assess drug resistance.
The best classifiers (with feature set F1), offer improvement
upon the baseline DA method for INH and PZA, potentially because
there are additional mutations to reported resistance-determinants,
or because there may be multivariate associations (i.e. co-occurrence
of resistance) or interactions between mutations within the 23 genes
considered in this study. The fact that machine learning methods did
disproportionately better with PZA could also because that there is
a large number of contributory variants for PZA resistance, com-
pared to most of the other drugs investigated. In the case of the best
classifiers with feature set F2, the improvement regarding to EMB,
CIP and SM could result from resistance co-occurrence, upon which
the machine learning models capitalize to improve its results. For
RIF, MOX and OFX, the improvement from using the best classi-
fiers with feature set F3 suggests there may be unknown associations
within genes suspected to be related to resistance. The likely inter-
pretation associated with F3 being the best classifier for some drugs,
is that additional mutations to reported resistance-determinants or
combinations of mutations (i.e. interactions) in the suspected genes
are more sensitive for identifying resistance to the considered drug.
Relatively higher performance obtained by the best classifier with
feature set F3 for MDR-TB detection may illustrates there is poten-
tial pattern related to drug resistance co-occurrence. The additional
SNP candidates to resistance-determinants within the 23 genes are
listed in Supplementary Material H.
In general, classifier performance with the F1 feature set remov-
ing known D.SNPs gave results that still outperformed DA in
improving AUC for all drugs. Our methods achieved at least 95%
AUC, except for MOX, OFX and SM, where poorer performance
might also be due to a result of there being small numbers of resist-
ant isolates for these drugs. This indicates that the best classifiers are
robust to the removal of D.SNPs, which supports the potential
application in whole genome sequencing especially when the resist-
ance mechanisms for some drugs remains incompletely understood.
It would be interesting to explore in future work whether perform-
ance further improves, or degrades, if either synonymous SNPs
[which can rarely be associated with resistance Ando et al. (2014)]
or SNPs across the entire genome (not just in genes previously asso-
ciated with drug resistance) are considered. Both would vastly
expand the size of the feature sets.
The machine learning approaches that we have investigated pro-
vide the greatest improvements in classification performance for
those drugs in which the mechanisms of resistance are less well-
understood. For PZA and SM, the baseline DA prediction achieved
relative high specificity, but very low sensitivity (58 and 63%,
respectively). For the same drugs, the machine learning methods
improved overall AUC by 10% (attaining 86 and 89% sensitivity,
respectively, while retaining >87% specificity). This improvement is
likely to be caused by patterns of resistance to multiple drugs that
the machine learning models can exploit. For instance, if an isolate
is resistant to PZA, it is also likely to be resistant to INH or RIF.
Table 1. Comparing performance between best classifier and DA-L for resistance prediction with 8 drugs and MDR-TB
Drug DA-L Best classifier
Sens Spec AUC Classifier (Feature set) Sens Spec AUC Classifier with F1* AUC
INH 936 0.3 996 0.1 96 6 0.0 RF(F1) 97† 6 0.3 94† 6 0.4 99† 6 0.0 RF(F1) 98†6 0.0
EMB 956 0.7 976 0.6 96 6 0.1 CBMM(F2) 97† 6 1.0 96† 6 0.6 99† 6 0.1 PM(F2) 99†6 0.1
RIF 946 0.5 986 0.3 96 6 0.1 CBMM(F3) 97† 6 0.4 97 6 0.4 99† 6 0.1 CBMM(F3) 99†6 0.1
PZA 696 1.4 1006 0.0 85 6 0.0 PM(F1) 84† 6 1.2 90† 6 1.1 95† 6 0.2 SVM-RBF(F1) 95†6 0.2
CIP 876 1.0 996 0.4 94 6 0.1 PM(F2) 96† 6 0.9 98 6 0.4 98† 6 0.3 PM(F2) 98†6 0.3
MOX 836 1.4 936 0.8 87 6 0.1 PM(F3) 95† 6 1.4 93 6 1.0 95† 6 0.4 PM(F3) 94†6 0.5
OFX 816 1.5 956 0.9 87 6 0.3 PM(F3) 96† 6 1.4 92 6 1.3 95† 6 0.5 PM(F3) 95†6 0.6
SM 636 1.8 986 0.6 81 6 0.1 SVM-RBF(F2) 87† 6 1.5 90† 6 1.0 91† 6 0.3 PM(F2) 92†6 0.2
MDR 906 0.7 1006 0.2 95 6 0.0 PM(F3) 96† 6 0.6 98† 6 0.5 100† 6 0.1 PM(F3) 100†6 0.0
Note: ‘D.SNPs’ refers to those SNPs known not to be causally involved with resistance mechanisms, and which are removed from F1 feature set in one experi-
ment. Sensitivity (sens) and specificity (spec) are shown with AUC, where results are reported as mean and standard error.
†
P-value is lower than 0.01 (P < 0.01). The P-value of performance measurement of the examined classifier compared to the DA-L was obtained by Wilcoxon
signed-rank test. Feature set F1* denotes the feature set F1 without D.SNPs.
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This can also be used to explain why all machine learning methods
with F1 and F2 were better than F3 for both PZA and SM in
Figure 3. While these co-occurrences may obscure the true mecha-
nistic basis of resistance, they are still practically useful when design-
ing a treatment plan for a patient.
Among the machine learning classifiers, PM and SVM-RBF rank as
the top two best-performing classifiers overall. The former integrates
prior knowledge of resistance determinant explicitly (though prior
knowledge about susceptibility determinants, lineage defining SNPs and
compensatory mutations was not included), and the latter suggests that
the method’s nonlinear model is suitable for unveiling nonlinear rela-
tionships among mutations in terms of resistance association for INH,
CIP and SM. We acknowledge our dataset was subset of the dataset in
Walker et al. (2015), from which the library of DA-L was derived. It is
expected that the DA-L would over-perform DA-D, however, this is not
true for EMB and second-line drugs (Supplementary Material F).
We note that our analysis was limited by low resistance, even for
INH and RIF there were not so many resistance cases. It is acknowl-
edged that there is trade-off between bias and variance in the
machine learning methods. We attempted to use cross-validation to
manage the trade-off for small dataset and only reported average
performance on testing set instead of training set. In the analysis of
selected clusters (Supplementary Material I), all methods resulted in
higher variance than that in the entire dataset. DA method was
more biased in the clusters than in the entire data (classification sen-
sitivity of DA was higher in clusters for INH and PZA up to 98%,
but lower for RIF, EMB and MDR-TB down to 81%); while the
machine learning classifiers gave similar performance with that
obtained when using the data as a whole.
5 Conclusion
We investigated several classifiers for resistance classification that
demonstrated the potential to model genetic data (e.g. SVM_RBF)
and take into account the prior knowledge and latent subgroup
structure (e.g. PM and CBMM). We applied the classifiers to three
different feature sets and the best-performing model outperformed
the baseline method (DA) in terms of sensitivity to resistance classifi-
cation. This work showed great potentials of machine learning in
improving resistance classification given high-dimensional genetic
data, especially when the underlying biological resistance mecha-
nism is poorly understood for many drugs. Use of the best model
examined in this paper to predict MTB resistance is promising to
improve patient outcomes and reduce risk of acquiring multi-drug
resistance. The validation on global samples will be the future work.
Limitation of our work is that the examined methods considered
ALL polymorphisms (and resistance-determining) to be the same
even though some polymorphisms might have different effects.
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